Glucose (CID 5793) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(1)
 
 
Inactive(29)
 
 
Inconclusive(2)
 
 
Unspecified(47)
 
 
Top Targets:
RIP(2)
 
 
HELICc(2)
 
 
Menin(2)
 
 
NR LBD ROR li..(2)
 
 
NR LBD TR(2)
 
 
BioAssay Types:
Literature(46)
 
 
 
Confirmatory(23)
 
 
Screening(5)
 
 
BioActivity Types:
Potency(23)
 
 
Ki(6)
 
 
IC50(4)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 79    Data Row: 79   Total Pages: 2   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID48415870]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
2
[SID104243011]
IC50 30Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins [AID377830, Type: Literature]
View
3
[SID104243011]
IC50 30Antioxidant activity assessed as authentic peroxynitrite free radical scavenging activity after 30 mins [AID377831, Type: Literature]
View
4
[SID104243011]
IC50 30Antioxidant activity assessed as 3-morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 30 mins [AID377832, Type: Literature]
View
5
[SID104243011]
Ki 1698.24Inhibitory activity against glycogen phosphorylase, activity expressed as -logKi [AID73810, Type: Literature]
View
6
[SID104243011]
Ki 1698.24Affinity on glycogen phosphorylase (GP) enzyme. [AID73821, Type: Literature]
View
7
[SID104243011]
Ki 1700Inhibition of rabbit glycogen phosphorylase B enzyme [AID73815, Type: Literature]
View
8
[SID104243011]
Ki 1700The compound was evaluated for the inhibition of glycogen phosphorylase [AID73819, Type: Literature]
View
9
[SID104243011]
Ki 7400Inhibitory activity against muscle Glycogen Phosphorylase b [AID141119, Type: Literature]
View
10
[SID104243011]
Ki 7400Inhibitory binding constant against glycogen phosphorylase B [AID73826, Type: Literature]
View
11
[SID104243011]
MIC 100000Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutination [AID381592, Type: Literature]
View
12
[SID104243011]
MIC 100000Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutination [AID381594, Type: Literature]
View
13
[SID104243011]
IC50 500000Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells [AID381596, Type: Literature]
View
14
[SID104243011]
 Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells relative to galactose [AID381597, Type: Literature]
View
15
[SID104243011]
 Activation of AMPKalpha in rat L6 cells assessed as ATP concentration per mg of protein at 5 mM [AID389773, Type: Literature]
View
16
[SID104243011]
 Activation of AMPKalpha in rat L6 cells assessed as ATP concentration per mg of protein at 23 mM [AID389774, Type: Literature]
View
17
[SID104243011]
 Inhibitory activity against Pig Skeletal Glycogen Phosphorylase b [AID73824, Type: Literature]
View
18
[SID104243011]
 Tested for inhibition constant against glycogen phosphorylase b [AID73825, Type: Literature]
View
19
[SID104243011]
 Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutination relative to galactose [AID381595, Type: Literature]
View
20
[SID104243011]
 Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutination relative to galactose [AID381593, Type: Literature]
View
21
[SID104243011]
 Duration of spinal anesthesia at the digits of the hind limbs was measured in sheep at dose 40(mg/kg) [AID204254, Type: Literature]
View
22
[SID104243011]
 Duration of spinal anesthesia at the weight support was measured in sheep at dose 40(mg/kg) [AID204259, Type: Literature]
View
23
[SID104243011]
 Ratio of catalytic constant (kcat)/Kinetic constant(Km) [AID226604, Type: Literature]
View
24
[SID104243011]
 Binding energy by using the equation deltaG obsd = -RT ln KD [AID227718, Type: Literature]
View
25
[SID104243011]
 Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system [AID156202, Type: Literature]
View
26
[SID104243011]
 Binding to POPC/GMI liposomes using biosensor system [AID156204, Type: Literature]
View
27
[SID104243011]
 Duration of spinal anesthesia at the anal region was measured in sheep at dose 40(mg/kg) [AID204248, Type: Literature]
View
28
[SID104243011]
 Inhibitory activity against rabbit muscle glycogen phosphorylase [AID73817, Type: Literature]
View
29
[SID104243011]
 Binding affinity against Glucose binding protein [AID74399, Type: Literature]
View
30
[SID104243011]
 Kinetic inhibition constant was evaluated by measuring the inhibition of the glycogen phosphorylase (GP) [AID73820, Type: other]
View
31
[SID104243011]
 Effective permeability measured in human. [AID21264, Type: Literature]
View
32
[SID104243011]
 pKa value of the compound; nm ='not measured' [AID26580, Type: Literature]
View
33
[SID104243011]
 Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology. [AID29845, Type: Literature]
View
34
[SID104243011]
 ClogP value of the compound; nd ='no data' [AID15712, Type: Literature]
View
35
[SID104243011]
 Compound was tested for inhibition of Human acrosin by aldohexoses [AID30427, Type: Literature]
View
36
[SID104243011]
 Binding affinity of the Corticosteroid-Binding Globulin Receptor with aldosterone [AID53797, Type: Literature]
View
37
[SID104243011]
 Acceptor substrate specificity toward Fucosyltransferase for the galactosides of GlcNAc with beta 1,3 or beta 1,4-linkages [AID71968, Type: other]
View
38
[SID104243011]
MIC In vitro flocculation inhibitory ability was determined towards Yeast cell wall lectin (KbWCL) [AID73340, Type: other]
View
39
[SID104243011]
 Absolute bioavailability in human [AID481439, Type: Literature]
View
40
[SID104243011]
 Effective permeability across human jejunum [AID481446, Type: Literature]
View
41
[SID104243011]
 Ratio of Kcat to Km for Neisseria meningitidis lgtC [AID500279, Type: Literature]
View
42
[SID104243011]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans [AID588211, Type: Literature]
View
43
[SID104243011]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents [AID588212, Type: Literature]
View
44
[SID104243011]
 Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents [AID588213, Type: Literature]
View
45
[SID104243011]
 Aqueous diffusivity at 37C [AID481441, Type: Literature]
View
46
[SID104243011]
 Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells [AID481442, Type: Literature]
View
47
[SID104243011]
 Octanol-water partition coefficient, log P of the compound [AID481444, Type: Literature]
View
48
[SID104243011]
 Inhibition of GluT1-mediated [14C]D-glucose uptake in Wistar rat brain at 20 mM by perfusion technique [AID350509, Type: Literature]Solute carrier family 2, facilitated glucose transporter member 1 [gi:121755]
View
49
[SID29218051]
Potency 42.2841qHTS for Inhibitors of Polymerase Kappa [AID588579, Type: confirmatory]DNA polymerase kappa [Homo sapiens] [gi:7705344]
View
50
[SID29218051]
Potency 42.2841qHTS for Inhibitors of Polymerase Kappa [AID588579, Type: confirmatory]DNA polymerase kappa [Homo sapiens] [gi:7705344]
View